{
    "clinical_study": {
        "@rank": "111103", 
        "arm_group": [
            {
                "arm_group_label": "LY2951742 Single Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Dose 1 of LY2951742 given subcutaneously once"
            }, 
            {
                "arm_group_label": "LY2951742 Single Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Dose 2 of LY2951742 given subcutaneously once"
            }, 
            {
                "arm_group_label": "LY2951742 Single Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "Dose 3 of LY2951742 given subcutaneously once"
            }, 
            {
                "arm_group_label": "LY2951742 Single Dose 4", 
                "arm_group_type": "Experimental", 
                "description": "Dose 4 of LY2951742 given subcutaneously once"
            }, 
            {
                "arm_group_label": "LY2951742 Multiple Dose", 
                "arm_group_type": "Experimental", 
                "description": "LY2951742 given subcutaneously once every 4 weeks for 12 weeks"
            }, 
            {
                "arm_group_label": "Placebo Single Dose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo given subcutaneously once"
            }, 
            {
                "arm_group_label": "Placebo Multiple Dose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo given subcutaneously once every 4 weeks for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate the safety of the study drug known as\n      LY2951742 in healthy Japanese and Caucasians.  The study will also investigate how the body\n      processes the drug and how the drug affects the body.  The study is expected to last about 5\n      to 8 months, depending on the arm."
        }, 
        "brief_title": "A Study of LY2951742 in Healthy Japanese and Caucasian Participants", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Migraine Disorders", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants are either Caucasian or first generation Japanese.\n\n          -  Participants' body mass index (BMI) is between 18.0 and 35.0 kilogram per meter\n             square (kg/ m^2).\n\n        Exclusion Criteria:\n\n          -  Participants are heavy caffeine drinkers defined by regular intake of more than 5\n             cups of coffee (or equivalent in xanthine containing beverages) per day, and/or are\n             unable or unwilling to abide by caffeine restrictions as specified in the protocol.\n\n          -  Participants are smoking within the previous 6 months.\n\n          -  Participants have received treatment with biologic agents (such as monoclonal\n             antibodies) within 3 months or 5 half-lives (whichever is longer) prior to dosing or\n             have received a vaccination within 1 month.\n\n          -  Participants have known allergies to LY2951742, related compounds or any components\n             of the formulation, or history of significant atopy.\n\n          -  Participants are allergies to either humanized monoclonal antibodies,\n             diphenhydramine, epinephrine, or methylprednisolone."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104765", 
            "org_study_id": "15435", 
            "secondary_id": "I5Q-MC-CGAE"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY2951742 Single Dose 1", 
                    "LY2951742 Single Dose 2", 
                    "LY2951742 Single Dose 3", 
                    "LY2951742 Single Dose 4", 
                    "LY2951742 Multiple Dose"
                ], 
                "description": "Administered subcutaneously.", 
                "intervention_name": "LY2951742", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Single Dose", 
                "description": "Administered subcutaneously.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Cypress", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90630"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "official_title": "A Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 Administered Subcutaneously to Japanese and Caucasian Healthy Subjects", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration", 
            "safety_issue": "Yes", 
            "time_frame": "Screening through Day 225"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104765"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum Concentration of LY2951742", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 through Day 225"
            }, 
            {
                "measure": "Area Under the Concentration Curve of LY2951742", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 through Day 225"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}